Watchlist Price Alert

Indivior (INDV)

NASDAQ: INDV · Real-Time Price · USD

11.91

-0.07 (-0.58%)

At close: May 05, 2025, 3:59 PM

11.67

-2.06%

After-hours: May 05, 2025, 07:58 PM EDT

-0.58% (1D)

Bid	11.67
Market Cap	1.49B
Revenue (ttm)	1.17B
Net Income (ttm)	2.78M
EPS (ttm)	-0.05
PE Ratio (ttm)	-238.3
Forward PE	6.33
Analyst	Buy

Ask	11.93
Volume	462,695
Avg. Volume (20D)	1,353,341
Open	12.14
Previous Close	11.98
Day's Range	11.91 - 12.22
52-Week Range	7.33 - 18.59
Beta	0.32

About INDV

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorph...

Sector Healthcare

IPO Date Dec 29, 2014

Employees 1,030

Stock Exchange NASDAQ

Ticker Symbol INDV

Website https://www.indivior.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for INDV stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 21.70% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+13.86%

Indivior shares are trading higher after the compa... Unlock content with Pro Subscription

2 months ago

-17.6%

Indivior shares are trading lower after the company issued FY25 net revenue guidance below estimates.

News

1 week ago · seekingalpha.com

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Indivior PLC (NASDAQ:INDV ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Ryan Preblick - CFO Conference Call Participan...

1 week ago · zacks.com

Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates

Indivior PLC (INDV) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.37 per share a year ago.

2 months ago · reuters.com

UK's Indivior appoints Joe Ciaffoni as CEO

British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.

2 months ago · seekingalpha.com

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

2 months ago · benzinga.com

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.

2 months ago · zacks.com

Indivior PLC (INDV) Q4 Earnings Meet Estimates

Indivior PLC (INDV) came out with quarterly earnings of $0.32 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.43 per share a year ago.